AlphaTON Capital (ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, issued a ...

Mesothelioma, cancer affecting different parts of the body, can have varying treatment approaches based on tumor location and cell types Epithelioid mesothelioma, the most prevalent cell type, shows ...

Malignant mesothelioma is a highly aggressive asbestos-related malignant neoplasm with unfavorable prognosis. The incidence of mesothelioma is still increasing in Japan and Western countries, with an ...

Estimating the prognosis in malignant pleural mesothelioma (MPM) remains challenging. Thus, the prognostic relevance of Ki67 was studied in MPM. The test cohort consisted of 187 patients from three ...

Patients with untreated mesothelioma may be able to avoid chemotherapy, say researchers reporting new survival data with the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy).

As described in the abstract, investigators will present first evidence that A2B receptor inhibition reduces the adenosine-mediated increase in PD-L1 in a human epithelioid mesothelioma cell line, ...

Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone.

Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A ...

FDA approved Opdivo and Yervoy for unresectable malignant pleural mesothelioma, the first new regimen in over 15 years. CheckMate-743 trial showed superior overall survival with Opdivo-Yervoy compared ...

CHICAGO — The addition of nintedanib to pemetrexed/cisplatin appeared safe and effective for the treatment of patients with malignant pleural mesothelioma, according to results from the LUME-Meso ...